Analyzing ALX Oncology (NASDAQ:ALXO) and Lumos Pharma (NASDAQ:LUMO)
Analyzing ALX Oncology (NASDAQ:ALXO) and Lumos Pharma (NASDAQ:LUMO)
ALX Oncology (NASDAQ:ALXO – Get Rating) and Lumos Pharma (NASDAQ:LUMO – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.
ALX肿瘤学(纳斯达克：ALXO-GET评级)和鲁莫斯医药(纳斯达克：LUMO-GET评级)都是小盘医疗公司，但哪一家更好？我们将根据两家公司的机构所有权、盈利能力、风险、收益、分析师建议、股息和估值等方面的实力进行比较。
Earnings & Valuation
收益与估值
This table compares ALX Oncology and Lumos Pharma's gross revenue, earnings per share and valuation.
此表比较了ALX肿瘤学和Lumos Pharma的毛收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ALX Oncology | $1.18 million | 481.02 | -$83.46 million | ($2.72) | -5.12 |
| Lumos Pharma | $230,000.00 | 307.37 | -$30.43 million | ($3.44) | -2.45 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| ALX肿瘤学 | 118万美元 | 481.02 | -8,346万元 | ($2.72) | -5.12 |
| 卢莫斯制药公司 | $230,000.00 | 307.37 | -3043万美元 | ($3.44) | -2.45 |
Lumos Pharma has lower revenue, but higher earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than Lumos Pharma, indicating that it is currently the more affordable of the two stocks.
Lumos Pharma的收入低于ALX肿瘤学，但收益高于ALX肿瘤学。ALX Oncology的市盈率低于Lumos Pharma，这表明它目前是两只股票中更负担得起的一只。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| ALX Oncology | N/A | -31.38% | -29.66% |
| Lumos Pharma | N/A | -33.81% | -29.78% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| ALX肿瘤学 | 不适用 | -31.38% | -29.66% |
| 卢莫斯制药公司 | 不适用 | -33.81% | -29.78% |
Institutional and Insider Ownership
机构和内部人持股
89.4% of ALX Oncology shares are held by institutional investors. Comparatively, 38.4% of Lumos Pharma shares are held by institutional investors. 49.9% of ALX Oncology shares are held by insiders. Comparatively, 15.9% of Lumos Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
ALX Oncology 89.4%的股份由机构投资者持有。相比之下，Lumos Pharma 38.4%的股份由机构投资者持有。ALX Oncology 49.9%的股份由内部人士持有。相比之下，Lumos Pharma 15.9%的股份由内部人士持有。强大的机构持股表明，大型基金管理公司、捐赠基金和对冲基金相信，一家公司有望实现长期增长。
Volatility & Risk
波动性与风险
ALX Oncology has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.
ALX Oncology的贝塔系数为2.21，这表明其股价的波动性比标准普尔500指数高121%。相比之下，Lumos Pharma的贝塔系数为1.23，这表明其股价的波动性比标准普尔500指数高23%。
Analyst Recommendations
分析师建议
This is a summary of current ratings and recommmendations for ALX Oncology and Lumos Pharma, as provided by MarketBeat.
这是由MarketBeat提供的对ALX肿瘤学和Lumos Pharma的当前评级和推荐的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ALX Oncology | 0 | 1 | 6 | 0 | 2.86 |
| Lumos Pharma | 0 | 0 | 3 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| ALX肿瘤学 | 0 | 1 | 6 | 0 | 2.86 |
| 卢莫斯制药公司 | 0 | 0 | 3 | 0 | 3.00 |
ALX Oncology currently has a consensus target price of $39.83, suggesting a potential upside of 185.95%. Lumos Pharma has a consensus target price of $24.00, suggesting a potential upside of 185.04%. Given ALX Oncology's higher possible upside, research analysts plainly believe ALX Oncology is more favorable than Lumos Pharma.
ALX Oncology目前的共识目标价为39.83美元，暗示潜在上涨185.95%。Lumos Pharma的共识目标价为24美元，暗示潜在上行185.04%。考虑到ALX肿瘤学更有可能的上行空间，研究分析师显然认为ALX肿瘤学比Lumos Pharma更有利。
Summary
摘要
ALX Oncology beats Lumos Pharma on 10 of the 13 factors compared between the two stocks.
与Lumos Pharma相比，ALX Oncology在13个因素中有10个击败了Lumos Pharma。
About ALX Oncology
关于ALX肿瘤学
(Get Rating)
(获取评级)
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
ALX Oncology Holdings Inc.是一家临床阶段的免疫肿瘤学公司，专注于为抗癌患者开发疗法。它的主要候选产品是ALX148，这是一种CD47阻断疗法，处于1b/2期临床试验，用于治疗骨髓增生异常综合征；用于治疗急性髓系白血病和非霍奇金淋巴瘤，以及一系列实体肿瘤适应症，包括头颈部鳞状细胞癌、人表皮生长因子受体2(HER2)阳性的胃/胃食道交界癌、HER2表达的乳腺癌和其他实体肿瘤。该公司的临床前产品包括Alta-002，一种SIRPA TRAAC，提供对癌症的先天和适应性免疫反应的方法。ALX Oncology Holdings Inc.与默克公司签署了一项合作协议，将对ALX148与培布罗珠单抗联合治疗头颈部癌症的患者进行第二阶段试验；ZymeWorks公司与默克公司签订了一项第一阶段试验，对ALX148与HER2靶向双特异性抗体zanidatamab在乳腺癌和其他实体肿瘤患者中的应用进行评估；Tallac Treeutics公司负责一种新型癌症免疫疗法的开发、制造和商业化。它还与Selexis SA和Crystal Bioscience，Inc.签署了许可协议。该公司成立于2015年，总部位于加利福尼亚州旧金山南部。
About Lumos Pharma
关于Lumos Pharma
(Get Rating)
(获取评级)
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Lumos制药公司是一家临床阶段的生物制药公司，专注于罕见疾病治疗药物的开发和商业化。它的主要候选治疗药物Lum-201是一种口服生长激素促分泌剂布洛莫伦，该药正处于第二阶段临床试验，用于治疗儿童生长激素缺乏症和其他罕见的内分泌疾病。该公司总部设在得克萨斯州奥斯汀。
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接受《ALX肿瘤学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对ALX肿瘤学和相关公司的最新新闻和分析师评级的每日简明摘要。